Metsera, INC Form 4 insider transactions

FMR LLC reports the disposition of Metsera, Inc. common stock following its acquisition by Pfizer Inc. for $65.60 cash per share plus a contingent value right.

ARCH Venture Partners entities and associated individuals reported the disposition of Metsera, Inc. common stock following its acquisition by Pfizer Inc. for $65.60 cash per share plus a CVR.

Metsera's Chief Medical Officer, Steven Marso, disposed of all common stock, restricted stock units, and stock options following the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Paul L. Berns, a director of Metsera, Inc., reported the disposition of all his direct and indirect beneficial ownership in Metsera common stock, restricted stock units, and stock options following the company's merger with Pfizer Inc. on November 13, 2025.

Metsera, Inc. Chief Legal Officer Matthew Lang's equity holdings converted into cash and contingent value rights following the company's acquisition by Pfizer Inc.

Population Health Partners GP, LLC reported the disposition of all its Metsera, Inc. common stock following the company's merger with a Pfizer Inc. subsidiary for $65.60 per share cash and a contingent value right.

Metsera Director Kristina Burow's equity and derivative holdings were converted into cash and contingent value rights following the company's acquisition by Pfizer Inc. for $65.60 per share.

Validae Health, L.P., a 10% owner of Metsera, Inc., distributed its entire holding of 12.7 million common shares to its limited and general partners.

Metsera Director Joshua Pinto reports the disposition of common stock, RSUs, and stock options following the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Metsera Director Jon P. Stonehouse disposed of common stock, restricted stock units, and stock options as part of the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Metsera, Inc.'s Chief Scientific Officer, Brian Hubbard, converted all his common stock, restricted stock units, and stock options into cash and contingent value rights following the company's merger with Pfizer Inc.

Metsera, Inc. Chief Financial Officer Christopher Visioli reported the conversion of his equity holdings into cash and contingent value rights following the company's acquisition by Pfizer Inc.

Clive Meanwell, Executive Chairman of Metsera, Inc., reported the disposition of all his Metsera securities following the company's acquisition by Pfizer Inc.

Metsera, Inc. President and CEO, Christopher Whitten Bernard, converted his equity holdings into cash and contingent value rights following the company's acquisition by Pfizer Inc.

FMR LLC, a 10% owner and director of Metsera, Inc., reported gifting 860,722 shares of common stock on November 10, 2025.

FMR LLC and its affiliated entities reported a series of transactions involving Metsera, Inc. common stock, including distributions without consideration and a small sale.

FMR LLC, a significant shareholder in Metsera, Inc., reported a disposition of 633,715 common shares as a gift.

FMR LLC filed an amended Form 4 to correct the reported number of Metsera, Inc. common shares indirectly acquired on September 2, 2025.

FMR LLC, a significant shareholder in Metsera, Inc., disclosed a series of internal share distributions and a small sale of common stock.

Director Joshua Pinto reports the acquisition of stock options and a transfer of existing options to Maple DE Holdings LLC.

Clive Meanwell, Executive Chairman of Metsera, Inc., reports the acquisition of stock options.

Kristina Burow, a director of Metsera, Inc., reported the acquisition of stock options exercisable for 16,125 shares of common stock, according to a Form 4 filing with the SEC.

Christopher Visioli, CFO of Metsera, Inc., was granted stock options for 150,000 shares of common stock on May 20, 2025, according to a Form 4 filing.

Matthew Lang, Chief Legal Officer of Metsera, Inc., reports the acquisition of stock options exercisable for 46,875 shares of common stock.

Christopher Whitten Bernard, President and CEO of Metsera, Inc., was granted stock options to purchase 348,750 shares of common stock at an exercise price of $29.25 per share, vesting monthly over four years.

Director Paul L. Berns reports the acquisition of stock options in Metsera, Inc. on May 20, 2025.

Brian Hubbard, Chief Scientific Officer of Metsera, Inc., was granted stock options for 120,000 shares of common stock on May 20, 2025, according to a Form 4 filing.

Steven Marso, Chief Medical Officer of Metsera, Inc., was granted stock options for 120,000 shares of common stock on May 20, 2025, according to a Form 4 filing.

Jon P. Stonehouse, a director of Metsera, Inc., was granted stock options to purchase 47,730 shares of common stock at $19.81 per share, vesting monthly over three years.

FMR LLC reports the conversion of Series Seed and Series A Preferred Stock to Common Stock in Metsera, Inc. following the company's initial public offering.